Pfizer Sees Once Daily Danuglipron In The “Reasonable Future”

 
• By Jessica Merrill

The obesity market offers big revenue potential but Pfizer’s oral GLP-1 candidate is currently dosed twice daily.

scale
Pfizer updated investors on its GLP-1 agonist for weight loss • Source: Shutterstock

More from Alimentary/Metabolic

More from Therapy Areas